Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan paying $560m for Naurex; stays quiet on rumored generics sale to Teva

This article was originally published in Scrip

Executive Summary

Allergan announced over the weekend that it agreed to pay $560m plus undisclosed milestone fees for novel depression drug developer Naurex, but the company remained quiet about the rumored sale of its generics business to Teva Pharmaceutical Industries for several billion dollars.

Advertisement
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029333

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel